Compare Samsara Inc (IOT) vs TG Therapeutics Inc (TGTX) Price & Performance

Samsara (IOT) trades at $41.22, up 1.75% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.20 vs. $0.16 expected, and revenue growth of 30% year-over-year. Analyst consensus is strongly bullish with a $51.15 price target, and recent news highlights partnerships and product launches like Samsara MCP for AI integration.

The outlook is positive given earnings momentum and large-customer expansion, but high valuation ratios (P/E 274.8, P/S 13.01) pose risks if growth slows. Key opportunities include sustained revenue growth and margin improvement, while risks involve competitive pressures and cash flow volatility from investing activities.

TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.

The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.